Your browser doesn't support javascript.
loading
Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre.
Palich, Romain; Agher, Rachid; Wetshikoy, Dimoke J; Cuzin, Lise; Seang, Sophie; Soulie, Cathia; Tubiana, Roland; Valantin, Marc-Antoine; Schneider, Luminita; Pourcher, Valérie; Marcelin, Anne-Geneviève; Assoumou, Lambert; Katlama, Christine.
Afiliação
  • Palich R; Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Agher R; Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Wetshikoy DJ; Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Cuzin L; Martinique University Hospital, Infectious and Tropical Diseases, Fort-De-France, FWI; CERPOP, INSERM UMR1295, Paul Sabatier University, Toulouse, France; and.
  • Seang S; Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Soulie C; Virology Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Tubiana R; Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Valantin MA; Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Schneider L; Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Pourcher V; Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Marcelin AG; Virology Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Assoumou L; Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
  • Katlama C; Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Sorbonne University, Paris, France.
J Acquir Immune Defic Syndr ; 92(2): 144-152, 2023 02 01.
Article em En | MEDLINE | ID: mdl-36257296
ABSTRACT

OBJECTIVES:

To assess whether antiretroviral therapy (ART) prescriptions differ between naive and virally suppressed HIV patients born in France (PBFs) and in Sub-Saharan Africa (PBSSAs).

SETTING:

Observational single-center study.

METHODS:

We included all PBFs and PBSSAs who entered into care at Pitié-Salpêtrière Hospital, Paris, France, from 01/01/2000 to 31/12/2018, with plasma HIV-RNA>200 copies/mL. We first compared the initial ART in naive PBFs and PBSSAs. Second, we compared the last-prescribed ART (including drug-reduced ART daily 2-drug regimens, daily 1-drug regimens and intermittent 3-drug regimens) in virally suppressed PBFs and PBSSAs, by focusing on patients in care in 2018 with HIV-RNA <50 copies for at least 24 months. A univariable and multivariable logistic regression model was used to assess the impact of geographical origin on ART prescriptions.

RESULTS:

A total of 1944 naive patients were included (915 PBSSAs and 1029 PBFs). PBSSAs were more frequently women, hepatitis B coinfected, with a lower pretherapeutic CD4 T-cell count, and most had tuberculosis at HIV diagnosis. After adjustment for confounders, PBSSAs were more likely to receive a first-line protease inhibitor-based regimen (OR 1.61, 95% CI 1.31 to 1.98), and less likely to receive an integrase inhibitor-based regimen (OR 0.61, 95% CI 0.42 to 0.88). Of the 968 virally suppressed patients (431 PBSSAs and 537 PBFs), PBSSAs were less likely to receive drug-reduced ART, including 2-drug regimens and intermittent three-drug regimens (OR 0.48, 95% CI 0.36 to 0.65).

CONCLUSIONS:

Differences in ART prescriptions between PBSSAs and PBFs were not only explained by different clinical and virologic situations. Personal motivations of doctors in choosing ART according to country of birth need to be explored.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Inibidores de Integrase de HIV / Fármacos Anti-HIV Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Inibidores de Integrase de HIV / Fármacos Anti-HIV Idioma: En Ano de publicação: 2023 Tipo de documento: Article